Literature DB >> 3940849

Hypercalcaemia. What does it signify?

R A Evans.   

Abstract

Hypercalcaemia can be caused by many disorders, but is most commonly due to primary hyperparathyroidism in outpatients, and to malignant disease in hospital inpatients. When mild (less than 3 mmol/L) it does not cause symptoms, but can have long term effects such as renal calculi. It is important that the aetiology of the hypercalcaemia be established, as it can reflect serious disease. In most patients the correct diagnosis can be suspected from clinical history and examination, and confirmed by laboratory tests and x-rays. The most difficult diagnostic problem is the patient with negative clinical findings, mild hypercalcaemia and mild renal impairment, when the parathyroid hormone level is normal or slightly elevated. When hypercalcaemia is severe (greater than 3.5 mmol/L), it can cause vomiting, polyuria, dehydration and renal impairment, and is then an important therapeutic problem. Therapy includes treatment of the cause, such as radiotherapy for malignant disease or surgery for primary hyperparathyroidism. In addition, it is usually necessary to treat the hypercalcaemia itself, and the initial step is always rehydration. If the plasma calcium concentration remains high, drug treatment must be added, the most effective and reliable agent being intravenous mithramycin. Aminohydroxypropylidene diphosphonate (APD), though less studied, may be equally useful in this situation. Glucocorticoids are not always effective, and phosphate may cause renal damage, particularly when given intravenously. For long term treatment of malignant hypercalcaemia, oral glucocorticoids and phosphate are often effective, and can be given in combination. When primary hyperparathyroidism cannot be corrected surgically, the hypercalcaemia (and hypercalciuria) are probably best treated with a low calcium diet and cellulose phosphate, a regimen also effective for the hypercalcaemia of sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3940849     DOI: 10.2165/00003495-198631010-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  22 in total

Review 1.  The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation.

Authors:  A M Parfitt
Journal:  Metabolism       Date:  1976-08       Impact factor: 8.694

2.  Does mild, asymptomatic hyperparathyroidism require surgery?

Authors:  F L Coe; M J Favus
Journal:  N Engl J Med       Date:  1980-01-24       Impact factor: 91.245

3.  Quantitative bone histology in the hypercalcemia of malignant disease.

Authors:  G D McDonnell; C R Dunstan; R A Evans; J N Carter; E Hills; S Y Wong; D R McNeil
Journal:  J Clin Endocrinol Metab       Date:  1982-12       Impact factor: 5.958

4.  Nephrogenous cyclic adenosine monophosphate as a parathyroid function test.

Authors:  A E Broadus; J E Mahaffey; F C Bartter; R M Neer
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

5.  Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community.

Authors:  H Heath; S F Hodgson; M A Kennedy
Journal:  N Engl J Med       Date:  1980-01-24       Impact factor: 91.245

6.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

7.  Clinically significant effect of protein concentration on ion-selective electrode measurements of ionised calcium.

Authors:  R B Payne
Journal:  Ann Clin Biochem       Date:  1982-07       Impact factor: 2.057

8.  What is tertiary hyperparathyroidism?

Authors:  P J Somerville; D J Tiller; R A Evans
Journal:  Aust N Z J Med       Date:  1975-12

9.  Primary hyperparathyroidism in paraneoplastic hypercalcaemia.

Authors:  M K Drezner; H E Lebovitz
Journal:  Lancet       Date:  1978-05-13       Impact factor: 79.321

Review 10.  Tumor hypercalcemia and "ectopic hyperparathyroidism".

Authors:  P Skrabanek; J McPartlin; D Powell
Journal:  Medicine (Baltimore)       Date:  1980-07       Impact factor: 1.889

View more
  1 in total

1.  Calcium free hemodialysis: experience in the treatment of 33 patients with severe hypercalcemia.

Authors:  C Camus; C Charasse; I Jouannic-Montier; P Seguin; Y L Tulzo; J Bouget; R Thomas
Journal:  Intensive Care Med       Date:  1996-02       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.